Bedrijfsoverzicht
Haleon plc is a leading global entity dedicated to the research, development, manufacture, and sale of diverse consumer healthcare products across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Operating within the Healthcare sector specifically under the Drug Manufacturers - Specialty & Generic industry, the company focuses on delivering oral health solutions such as toothpastes and mouthwashes to consumers worldwide. The enterprise demonstrates significant scale with a market capitalization of $43.86B and an annual revenue of $11.03B, supported by a workforce of 24,535 employees. These valuation and revenue figures indicate that Haleon plc holds a substantial position as a major player in the consumer healthcare market, reflecting its established footprint and capacity to generate consistent cash flows from a broad product portfolio.
Financiële gezondheid
The company reported a total revenue of $11.03B and a net income of $1.67B for the trailing twelve months, while generating an EBITDA of $2.74B. The substantial gap between the $11.03B revenue and the $1.67B net income reveals a cost structure where operating expenses, including cost of goods sold, research, and administrative costs, consume approximately 84.9% of total revenue before interest and taxes. Haleon plc maintains a free cash flow of $1.40B, which provides the organization with significant financial flexibility to fund ongoing research initiatives, manage capital expenditures, or return value to shareholders without relying on external financing. The company's profitability is characterized by a gross margin of 64.8%, an operating margin of 23.2%, and a profit margin of 15.1%, indicating efficient production processes and a pricing power that allows for healthy operating leverage. Regarding liquidity and leverage, the firm holds $1.35B in cash against $8.63B in debt, resulting in a debt-to-equity ratio of 52.37, which suggests a balance sheet that is moderately leveraged given the high proportion of debt relative to equity. The current ratio stands at 0.92, indicating that the company's current assets are slightly lower than its current liabilities, which implies a need for careful management of short-term obligations to maintain solvency. Return metrics show a return on equity of 10.3% and a return on assets of 4.7%, revealing that management generates a solid return for shareholders relative to their equity investment, while the return on assets reflects the capital-intensive nature of the pharmaceutical and consumer goods manufacturing business.
Waarderingsbeoordeling
Haleon plc trades with a trailing P/E ratio of 19.68 and a forward P/E of 16.29, where the difference between these multiples implies that the market expects earnings growth to accelerate in the coming year compared to historical performance. The price-to-book ratio is recorded at 1.99, indicating that the market values the company at nearly twice its book value, suggesting a premium assigned to the brand equity, intellectual property, and stable cash generation capabilities inherent in the consumer healthcare sector. Alternative valuation metrics such as the price-to-sales ratio of 3.98 and an EV/EBITDA of 34.63 further contextualize the stock's valuation relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. The 52-week price range for the ticker HLN spans from a low of $8.71 to a high of $11.42, providing a historical context for price volatility and trading ranges over the past year. The beta value of 0.33 indicates that the stock exhibits low volatility relative to the broader market, moving less than half the magnitude of the overall market index during periods of fluctuation.
Growth & Income
Revenue growth for the trailing twelve months is 0.6%, while earnings growth reaches 92.0%, demonstrating that net income is expanding at a rate significantly faster than top-line sales, which often points to cost optimization or a high-margin product mix adjustment. As a dividend payer, Haleon plc offers a dividend yield of 1.9% with a payout ratio of 37.1%, suggesting that the dividend is highly sustainable as the payout ratio is well below the 100% threshold and comfortably covered by the strong free cash flow generation. The disparity between revenue growth and earnings growth highlights an operational efficiency drive where profitability improvements outpace volume or price increases in the current fiscal period. Overall, the company presents a growth and income profile characterized by stable revenue streams, accelerating earnings, and a consistent, conservative dividend policy suitable for income-focused portfolios seeking lower volatility assets.